Advances in the development of new biologics in inflammatory bowel disease

Biologics have revolutionized the therapeutic approach in inflammatory bowel disease (IBD). Anti-tumor necrosis factor (anti-TNF) agents infliximab and adalimumab currently constitute the major biological therapy in IBD. Additional anti-TNFs such as golimumab and other new biologics are currently be...

Descripción completa

Detalles Bibliográficos
Autores principales: Ungar, Bella, Kopylov, Uri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2016
Materias:
Invited Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923809/
https://www.ncbi.nlm.nih.gov/pubmed/27366024
http://dx.doi.org/10.20524/aog.2016.0027
_version_ 1782439755955306496
author Ungar, Bella
Kopylov, Uri
author_facet Ungar, Bella
Kopylov, Uri
author_sort Ungar, Bella
collection PubMed
description Biologics have revolutionized the therapeutic approach in inflammatory bowel disease (IBD). Anti-tumor necrosis factor (anti-TNF) agents infliximab and adalimumab currently constitute the major biological therapy in IBD. Additional anti-TNFs such as golimumab and other new biologics are currently being developed for both anti-TNF-naïve and -resistant patients. These include anti-integrins (vedolizumab and etrolizumab), a JAK inhibitor (tofacitinib) and an anti-anti-interleukin (IL)-23 and IL-12 antibody (ustekinumab), among additional drugs in development. The following review discusses the indications, efficacy and safety issues for these novel medications.
format Online
Article
Text
id pubmed-4923809
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hellenic Society of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-49238092016-07-01 Advances in the development of new biologics in inflammatory bowel disease Ungar, Bella Kopylov, Uri Ann Gastroenterol Invited Review Biologics have revolutionized the therapeutic approach in inflammatory bowel disease (IBD). Anti-tumor necrosis factor (anti-TNF) agents infliximab and adalimumab currently constitute the major biological therapy in IBD. Additional anti-TNFs such as golimumab and other new biologics are currently being developed for both anti-TNF-naïve and -resistant patients. These include anti-integrins (vedolizumab and etrolizumab), a JAK inhibitor (tofacitinib) and an anti-anti-interleukin (IL)-23 and IL-12 antibody (ustekinumab), among additional drugs in development. The following review discusses the indications, efficacy and safety issues for these novel medications. Hellenic Society of Gastroenterology 2016 2016-03-24 /pmc/articles/PMC4923809/ /pubmed/27366024 http://dx.doi.org/10.20524/aog.2016.0027 Text en Copyright: © Hellenic Society of Gastroenterology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Invited Review
Ungar, Bella
Kopylov, Uri
Advances in the development of new biologics in inflammatory bowel disease
title Advances in the development of new biologics in inflammatory bowel disease
title_full Advances in the development of new biologics in inflammatory bowel disease
title_fullStr Advances in the development of new biologics in inflammatory bowel disease
title_full_unstemmed Advances in the development of new biologics in inflammatory bowel disease
title_short Advances in the development of new biologics in inflammatory bowel disease
title_sort advances in the development of new biologics in inflammatory bowel disease
topic Invited Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923809/
https://www.ncbi.nlm.nih.gov/pubmed/27366024
http://dx.doi.org/10.20524/aog.2016.0027
work_keys_str_mv AT ungarbella advancesinthedevelopmentofnewbiologicsininflammatoryboweldisease
AT kopylovuri advancesinthedevelopmentofnewbiologicsininflammatoryboweldisease

Ejemplares similares